



www.MedChemExpress.com

Inhibitors, Agonists, Screening Libraries











STING











Stimulator of Interferon Genes; TMEM173; MITA; ERIS; MPYS

STING (Stimulator of Interferon Genes) is an endoplasmic-reticulum (ER)-membrane protein that induced innate immunity for anti-microbial by activating the expression of type I IFN and other inflammatory cytokines. The activation of STING is mediated by cyclic dinucleotides (cAMP, cGMP and cGAMP) produced by DNA sensors (such as cGAS) from cytosolic DNA.

As reported, cGAS-STING pathway can be activated not only by viral and bacterial DNA, but also self-DNA such as tumor-derived DNA. Hence, activating of STING will induce tumor cell senescence, inflammation, and anti-tumor immunity and play important roles in tumor immunity. Small molecules capable of triggering STING are effective at blocking virus replication, enhancing vaccine efficacy, and facilitating immune response to cancer cells.

STING Inhibitors, Agonists, Antagonists & Activators


<p>2',3'-cGAMP (2'-3'-cyclic GMP-AMP) Cat. No.: HY-100564</p> <p>2',3'-cGAMP (2'-3'-cyclic GMP-AMP) is an endogenous cGAMP in mammalian cells. 2',3'-cGAMP binds to STING with a high affinity and is a potent inducer of interferon-β (IFNβ). 2',3'-cGAMP is produced in mammalian cells in response to DNA in the cytoplasm.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p> 	<p>2',3'-cGAMP sodium (2'-3'-cyclic GMP-AMP sodium) Cat. No.: HY-100564A</p> <p>2',3'-cGAMP sodium (2'-3'-cyclic GMP-AMP sodium) is an endogenous cGAMP in mammalian cells. 2',3'-cGAMP sodium binds to STING with a high affinity and is a potent inducer of interferon-β (IFNβ). 2',3'-cGAMP sodium is produced in mammalian cells in response to DNA in the cytoplasm.</p> <p>Purity: 98.82% Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg</p> 
<p>ADU-S100 (MIW815; ML RR-S2 CDA) Cat. No.: HY-12885</p> <p>ADU-S100 (MIW815), an activator of stimulator of interferon genes (STING), leads to potent and systemic tumor regression and immunity.</p> <p>Purity: 99.53% Clinical Data: Phase 2 Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg</p> 	<p>ADU-S100 ammonium salt (MIW815 ammonium salt; ML RR-S2 CDA ammonium salt) Cat. No.: HY-12885B</p> <p>ADU-S100 ammonium salt (MIW815 ammonium salt), an activator of stimulator of interferon genes (STING), leads to potent and systemic tumor regression and immunity.</p> <p>Purity: 99.44% Clinical Data: Phase 2 Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg</p> 
<p>ADU-S100 disodium salt (MIW815 disodium salt; ML RR-S2 CDA disodium salt) Cat. No.: HY-12885A</p> <p>ADU-S100 disodium salt (MIW815 disodium salt) is an activator of stimulator of interferon genes (STING).</p> <p>Purity: 98.83% Clinical Data: Phase 2 Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg</p> 	<p>C-176 Cat. No.: HY-112906</p> <p>C-176 is a strong and covalent mouse STING inhibitor.</p> <p>Purity: 98.10% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>C-178 Cat. No.: HY-123963</p> <p>C-178 is a potent and selective covalent inhibitor of STING. C-178 binds to Cys91 and suppresses the STING responses elicited by distinct bona fide activators in mouse but not human.</p> <p>Purity: 99.90% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 	<p>c-di-AMP (Cyclic diadenylate; Cyclic-di-AMP) Cat. No.: HY-12326</p> <p>c-di-AMP (Cyclic diadenylate) is a STING agonist, which binds to the transmembrane protein STING thereby activating the TBK3-IRF3 signaling pathway, subsequently triggering the production of type I IFN and TNF.</p> <p>Purity: 99.29% Clinical Data: No Development Reported Size: 500 µg, 1 mg</p> 
<p>c-di-AMP sodium (Cyclic diadenylate sodium; Cyclic-di-AMP sodium) Cat. No.: HY-12326A</p> <p>c-di-AMP (Cyclic diadenylate) sodium is a STING agonist, which binds to the transmembrane protein STING thereby activating the TBK3-IRF3 signaling pathway, subsequently triggering the production of type I IFN and TNF.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p> 	<p>CCCP (Carbonyl cyanide 3-chlorophenylhydrazone; Carbonyl Cyanide m-Chlorophenylhydrazone) Cat. No.: HY-100941</p> <p>CCCP is an oxidative phosphorylation uncoupler. CCCP induces activation of PINK1 leading to Parkin Ser65 phosphorylation.</p> <p>Purity: 99.83% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 50 mg</p> 



IACS-8803

Cat. No.: HY-130115

IACS-8803 is a highly potent cyclic dinucleotide **STING** agonist with robust systemic antitumor efficacy.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Omaveloxolone

(RTA 408)

Cat. No.: HY-12212

Omaveloxolone (RTA 408) is an antioxidant inflammation modulator (AIM), which activates **Nrf2** and suppresses nitric oxide (NO). Omaveloxolone attenuates osteoclastogenesis by inhibiting **STING** dependent NF- κ b signaling.




Purity: 99.40%
Clinical Data: Phase 2
Size: 10 mM \times 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

STING agonist-1

(G10)

Cat. No.: HY-19711

STING agonist-1 (G10) is human-specific **STING** agonist that elicits antiviral activity against emerging Alphaviruses. G10 potently blocks replication of Alphavirus species Venezuelan Equine Encephalitis Virus (VEEV) with **IC₅₀** of 24.57 μ M.




Purity: 99.93%
Clinical Data: No Development Reported
Size: 10 mM \times 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

STING agonist-3

Cat. No.: HY-103665

STING agonist-3, extracted from patent WO2017175147A1 (example 10), is a selective and non-nucleotide **STING** agonist with a **pEC₅₀** and **pIC₅₀** of 7.5 and 9.5, respectively.




Purity: 99.28%
Clinical Data: No Development Reported
Size: 10 mM \times 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

STING agonist-3 trihydrochloride

Cat. No.: HY-103665A

STING agonist-3 trihydrochloride, extracted from patent WO2017175147A1 (example 10), is a selective and non-nucleotide small-molecule **STING** agonist with a **pEC₅₀** and **pEC₅₀** of 7.5 and 9.5, respectively.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

STING agonist-4

Cat. No.: HY-123943

STING agonist-4 is a stimulator of Interferon Genes (**STING**) receptor agonist with an apparent inhibitory constant (**IC₅₀**) of 20 nM.




Purity: 99.52%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

STING ligand-1

Cat. No.: HY-114399

STING ligand-1 is a lead **STING** ligand with an **IC₅₀** of 68 nM for HAQ **STING**.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Vadimezan

(DMXAA; ASA-404)

Cat. No.: HY-10964

Vadimezan (DMXAA; ASA-404), the tumor vascular disrupting agent (tumor-VDA), is a murine agonist of the stimulator of interferon genes (**STING**) and also a potent inducer of type I IFNs and other cytokines. Vadimezan has anti-influenza virus H1N1-PR8 activities.



Purity: 99.81%
Clinical Data: Phase 3
Size: 10 mM \times 1 mL, 5 mg, 10 mg, 50 mg, 100 mg